Amygdalin and Cancer

Share this content:
While some in vitro data suggests anticancer activity, animal and in-human studies fail to show efficacy and the risk of cyanide toxicity make amygdalin not recommended for use.
While some in vitro data suggests anticancer activity, animal and in-human studies fail to show efficacy and the risk of cyanide toxicity make amygdalin not recommended for use.

Amygdalin, also referred to as laetrile, is a cyanogenic glucoside found in fruit pits, raw nuts, and some other plants such as lima beans and sorghum.1 Although they are often used interchangeably, laetrile is a purified form of amygdalin. Though sometimes called vitamin B-17, amygdalin is not officially recognized as a vitamin.

Amygdalin became popular in the 1970s as an anticancer therapy, but after a phase 2 clinical trial demonstrated both no antitumor activity and a risk of cyanide poisoning, the U.S. Food and Drug Administration banned its use.2 An internet search, however, returns multiple hits touting the anticancer activity of amygdalin and the efforts of the FDA or pharmaceutical industry to “cover up” its efficacy. It is readily available through online retailers.

In Vitro and Animal Studies

In vitro studies have suggested anticancer activity across multiple tumor cell types, including inhibition of proliferation, migration, and invasion.1 More recent studies are consistent with these earlier reports, with studies demonstrating that amygdalin inhibits tumor cell migration, invasion, and adhesion, and at higher doses, proliferation in renal cell carcinoma, breast, bladder, prostate, and non-small cell lung cancer cell lines.3-7

Most animal studies, however, failed to show antitumor activity for various induced and xenograft tumors.1

In-Human Studies

Positive case reports in the 1970s spurred the National Cancer Institute to initiate phase 1 and 2 trials. The phase 2 trial conducted by the NCI evaluated 175 patients with cancer, primarily of the lung, breast, and colorectal regions.8 The amygdalin used in the study was naturally derived from apricot pits and was administered at doses accepted as standard at the time. Patients received 21 daily intravenous injections of 4.5 g/m2 followed by oral maintenance therapy at 0.5 g three times daily. Patients also followed a “metabolic therapy” program that consisted of a diet with enzyme and vitamin supplements. The only tumor response reported was a single partial response that lasted for 10 weeks. Cyanide toxicity, however, was noted particularly with oral administration. Other potential adverse effects considered related to amygdalin were dermatitis, headache, dizziness, mental obtundation, nausea, and vomiting. One patient experienced tachycardia and dyspnea after dosing.

A systematic review found no randomized controlled trials that have evaluated amygdalin and concluded that there are no data to support its efficacy, but the risk of cyanide poisoning should discourage its use.2 Cyanide poisoning occurs due to hydrolysis of amygdalin in the gastrointestinal tract by bacterial and plant beta-glucosidase, which is consistent with the finding that this toxicity is associated with oral administration.1 Several recent case reports further support the risk of cyanide poisoning, including that of a 73-year-old woman with pancreatic cancer and a 4-year-old child with ependymoma.9,10

Conclusions

Though in vitro data continue to suggest anticancer activity of amygdalin, animal data and in-human studies have failed to show efficacy. There is a risk of cyanide toxicity with amygdalin use, especially when ingested orally. Therefore, amygdalin is not recommended for use.

References

  1. PDQ Integrative, Alternative, and Complementary Therapies Editorial Board. Laetrile/Amygdalin (PDQ®): Health Professional Version. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-2016 Dec 21.
  2. Milazzo S, Horneber M. Laetrile treatment for cancer (Review). Cochrane Database Syst Rev. 2015;4:CD005476. doi: 10.1002/14651858.CD005476.pub4
  3. Juengel E, Afschar M, Makarevic J, et al. Amygdalin blocks the in vitro adhesion and invasion of renal cell carcinoma cells by an integrin-dependent mechanism. Int J Mol Med. 2016;37:843-850. doi: 10.3892/ijmm.2016.2454
  4. Lee HM, Moon A. Amygdalin regulates apoptosis and adhesion in Hs578T triple-negative breast cancer cells. Biomol Ther (Seoul). 2016;24:61-66. doi: 10.4062/biomolther.2015.172
  5. Makarevic J, Rutz J, Juengel E, et al. Amygdalin influences bladder cancer cell adhesion and invasion in vitro. PLoS ONE. 2014;9:e110244. doi: 10.1371/journal.pone.0110244
  6. Makarevic J, Tsaur I, Juengel E, et al. Amygdalin delays cell cycle progression and blocks growth of prostate cancer cells in vitro. Life Sci. 2016;147:137-42. doi: 10.1016/j.lfs.2016.01.039
  7. Qian L, Xie B, Wang Y, Qian J. Amygdalin-mediated inhibition of non-small cell lung cancer cell invasion in vitro. Int J Clin Exp Pathol. 2015;8:5363-5670.
  8. Moertel CG, Fleming TR, Rubin J, et al. A clinical trial of amygdalin (laetrile) in the treatment of human cancer. N Engl J Med. 1982;306:201-206.
  9. Dang T, Nguyen C, Tran PN. Physician beware: severe cyanide toxicity from amygdalin tablets ingestion. Case Rep Emerg Med. 2017;4289527. doi: 10.1155/2017/4289527
  10. Sauer H, Wollny C, Oster I, et al. Severe cyanide poisoning from an alternative medicine treatment with amygdalin and apricot kernels in a 4-year-old child. Wien Med Wochenschr. 2015;165:185-188. doi: 10.1007/s10354-014-0340-7

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs